BIASIOLO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.785
AS - Asia 2.460
EU - Europa 1.930
SA - Sud America 615
AF - Africa 535
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 25
Totale 12.411
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.505
SG - Singapore 756
CN - Cina 650
BR - Brasile 430
HK - Hong Kong 342
IT - Italia 309
DE - Germania 284
FI - Finlandia 215
SE - Svezia 157
PL - Polonia 132
VN - Vietnam 130
GB - Regno Unito 103
UA - Ucraina 103
RU - Federazione Russa 77
FR - Francia 74
IN - India 69
NL - Olanda 59
AT - Austria 45
MX - Messico 31
EC - Ecuador 30
ES - Italia 26
IE - Irlanda 26
JP - Giappone 26
AR - Argentina 25
CA - Canada 25
TR - Turchia 25
AE - Emirati Arabi Uniti 23
CI - Costa d'Avorio 23
KR - Corea 23
SA - Arabia Saudita 23
JO - Giordania 22
KG - Kirghizistan 22
MA - Marocco 22
VE - Venezuela 21
AL - Albania 20
CY - Cipro 20
TN - Tunisia 20
CO - Colombia 19
CZ - Repubblica Ceca 19
EG - Egitto 19
ET - Etiopia 19
ML - Mali 19
PH - Filippine 19
BD - Bangladesh 18
BE - Belgio 18
LC - Santa Lucia 18
MN - Mongolia 18
PE - Perù 18
PY - Paraguay 18
TT - Trinidad e Tobago 18
UY - Uruguay 18
ZA - Sudafrica 18
NZ - Nuova Zelanda 17
AO - Angola 16
GA - Gabon 16
IR - Iran 16
LA - Repubblica Popolare Democratica del Laos 16
LB - Libano 16
LY - Libia 16
MR - Mauritania 16
NP - Nepal 16
PK - Pakistan 16
TW - Taiwan 16
UZ - Uzbekistan 16
AZ - Azerbaigian 15
BF - Burkina Faso 15
CG - Congo 15
CL - Cile 15
IS - Islanda 15
JM - Giamaica 15
ME - Montenegro 15
MW - Malawi 15
PR - Porto Rico 15
PT - Portogallo 15
AM - Armenia 14
CU - Cuba 14
DO - Repubblica Dominicana 14
HN - Honduras 14
HR - Croazia 14
IL - Israele 14
MY - Malesia 14
NE - Niger 14
PA - Panama 14
SD - Sudan 14
SK - Slovacchia (Repubblica Slovacca) 14
YE - Yemen 14
YT - Mayotte 14
BA - Bosnia-Erzegovina 13
BG - Bulgaria 13
CR - Costa Rica 13
CW - ???statistics.table.value.countryCode.CW??? 13
GT - Guatemala 13
ID - Indonesia 13
IQ - Iraq 13
RO - Romania 13
AU - Australia 12
BJ - Benin 12
BZ - Belize 12
CH - Svizzera 12
CV - Capo Verde 12
Totale 11.858
Salva come PNG Salva come JPEG
Città #
Fairfield 787
Chandler 577
Ashburn 532
Jacksonville 488
Singapore 487
Woodbridge 476
Houston 415
Wilmington 337
Hong Kong 332
Cambridge 316
Ann Arbor 310
Seattle 278
Boardman 173
Princeton 161
Santa Clara 151
Beijing 147
Bytom 112
Helsinki 97
Padova 96
San Diego 91
Nanjing 83
Des Moines 75
Medford 73
Munich 71
Roxbury 60
Dong Ket 54
Los Angeles 51
Dearborn 45
Guangzhou 41
Pune 36
Shenyang 35
São Paulo 35
Hefei 34
Nuremberg 29
Changsha 25
Jinan 24
Milan 24
Abidjan 23
Hebei 23
Ho Chi Minh City 23
London 23
Nanchang 23
Amman 22
Bishkek 22
Turku 21
Buffalo 20
Falls Church 20
Vienna 20
Bamako 19
Dublin 19
New York 19
Hanoi 18
Brooklyn 17
Ulan Bator 17
Castries 16
Libreville 16
Luanda 16
Norwalk 16
Chicago 15
Montevideo 15
Nouakchott 15
Rome 15
Rio de Janeiro 14
Tokyo 14
Addis Ababa 13
Baku 13
Detroit 13
Havana 13
Jiaxing 13
Kunming 13
Lima 13
Panama City 13
Tashkent 13
Yerevan 13
Cotonou 12
Council Bluffs 12
Guayaquil 12
Lusaka 12
Podgorica 12
Vientiane 12
Warsaw 12
Auckland 11
Boston 11
Conakry 11
Dallas 11
Dushanbe 11
Falkenstein 11
Kigali 11
Niamey 11
Praia 11
Quito 11
Redondo Beach 11
San Francisco 11
Shanghai 11
Willemstad 11
Accra 10
Andorra la Vella 10
Bologna 10
Dakar 10
Djibouti 10
Totale 8.077
Salva come PNG Salva come JPEG
Nome #
Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles 251
PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting 221
SCCA1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity 210
Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma 174
APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation. 173
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 166
SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity 164
Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma 159
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 156
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study 148
Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. 146
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 144
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment 143
SQUAMOUS CELL CARCINOMA ANTIGEN- IMMUNOGLOBULIN M (SCCA-IGM) AS BIOMARKER IN LIVER DISEASE: BIOLOGICAL ASPECTS AND CLINICAL APPLICATIONS 142
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 142
ANTIPHOSPHOLIPID ANTIBODIES ARE NOT PRESENT IN THE MEMBRANE OF GEL-FILTERED PLATELETS OF PATIENTS WITH IGG ANTICARDIOLIPIN ANTIBODIES, LUPUS ANTICOAGULANT AND THROMBOSIS 141
Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming 139
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 137
The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. 137
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 136
Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study 131
A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation 131
Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis 131
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants 130
A comparison of lupus anticoagulant-positive patients with clinical picture of Antiphospholipid syndrome and those without 130
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients 130
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 129
BINDING OF AUTOIMMUNE CARDIOLIPIN-REACTIVE ANTIBODIES TO HEPARIN - A MECHANISM OF THROMBOSIS 126
Serpinb3 is overexpressed in the liver in presence of iron overload 126
SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells 126
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome 125
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. 123
Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma 121
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. 121
PURIFICATION OF ANTICARDIOLIPIN AND LUPUS ANTICOAGULANT ACTIVITIES BY USING CARDIOLIPIN IMMOBILIZED ON AGAROSE BEADS 120
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 118
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface 117
Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins 116
[Anti-beta(2) glycoprotein I beta(2) glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases 115
[IgG anti-beta 2-glycoprotein I beta 2-glycoprotein I] immune complexes in patients with antiphospholipid (aPL) syndrome 115
1-Piperidine Propionic Acid Protects from Septic Shock Through Protease Receptor 2 Inhibition 113
HEPATIC PROGENITOR CELLS OVEREXPRESS SERPINB3 IN A MOUSE MODEL OF FULMINANT HEPATITIS 112
Hepatic progenitor cells overexpress SERPINB3 in a mouse model of fulminant hepatitis 111
Cellule progenitrici epatiche esprimono SERPINB3b in un modello murino di epatite fulminante 109
RUOLO DI SERPINB3 ELLA PROGRESSIONE DELLA MALATTIA EPATICA 109
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 108
Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis 108
HPYPOXYA UP-REGULATES SERPINB3 IN HEPATIC CANCER CELLS: A HIF-2a ASSOCIATED EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 104
CARATTERIZZAZIONE BIOLOGICA E FUNZIONE DELLA NUOVA ISOFORMA SCCA-PD 104
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic anticoagulant therapy: a prospective multicenter study 104
Increased antiprotease activity of the SerpinB3 polymorphic variant SCCA-PD 103
COMBINING SCCA-IGM AND AFP-IGM LEVELS INCREASES ACCURACY OF HEPATOCELLULAR CARCINOMA DETECTION 102
Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients 102
SERPINB3 is associated with longer survival in transgenic mice. 102
Engineered EVs for oxidative stress protection 101
Low intensity warfarin therapy. 100
Anti phospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purifled IgG with anticardiolipin and anti-beta 2-glycoprotein I activity 99
CHARACTERIZATION OF SCCA-1(SERPINB3) ISOFORMS IN HEPATOCELLULAR CARCINOMA 99
SCCA-IGM USEFULNESS TO MONITOR PATIENTS WITH CIRRHOSIS IS NOT AFFECTED BY INTERFERING IGM'S 98
SERPINB3 AS A PRO-INFLAMMATORY MEDIATOR IN THE PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE. 97
1-Piperidine Propionic Acid as an Allosteric Inhibitor of Protease Activated Receptor-2 97
HYPOXIA UP-REGULATES SERPINB3 IN HEPG2 CELLS: A REDOX SENSITIVE EVENT RELATED TOEPITHELIAL TO MESENCHYMAL TRANSITIONAND INVASIVENESS 97
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 97
SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) ENHANCES LIVER REGENERATION AFTER PARTIAL HEPATECTOMY 97
REVERSAL OF EXCESSIVE EFFECT OF REGULAR ANTICOAGULATION - LOW ORAL DOSE OF PHYTONADIONE (VITAMIN-K1) COMPARED WITH WARFARIN DISCONTINUATION 96
Modulazione dei livelli di IL-6 nella rigenerazione epatica da parte di SERPINB3 ed estrogeni. Analisi in un modello di topo transgenico 96
Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA) 95
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 95
SERPINB3 modulates TGF-beta expression in chronic liver disease. 93
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 92
Sex dependent IL-6 deregulation by SERPINB3 in a transgenic mouse model 91
The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation 90
Effect of anti-beta-2-glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis 90
Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity 90
Autoimmune antiphospholipid antibodies: What is their true target? 89
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden) 88
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 87
SCCA1-IGM AND SCCA2-IGM COMPARED WITH TOTAL SCCA-IGM FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 86
COMPORTAMENTO DI SCCA-IgM NEL SIERO DI BAMBINI HBeAg POSITIVI SEGUITI NEL TEMPO 86
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 86
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma 86
SEX DEPENDENT IL-6 DEREGULATION BY SERPINB3 IN A TRANSGENIC MOUSE MODEL 85
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothombin time monitor (Coagucheck) 85
Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma 84
CIRCULATING SURVIVIN-IGM IS A NOVEL CANDIDATE BIOMARKER OF CIRRHOSIS AND INCREASES WITH CHILD SCORE IN PATIENTS AFFECTED BY LIVER DISEASES 82
LRP-1 BINDS SERPINB3 AND MEDIATES ITS MIGRATORY ACTIVITY 82
The Protease Activated Receptor 2 - CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of Non-Alcoholic Steatohepatitis 81
Overexpression of SERPINB3 in hepatic progenitor cells in a mouse model of acute liver injury 81
OVEREXPRESSION OF SERPINB3 IN HEPATIC PROGENITOR CELLS IN A MOUSE MODEL OF ACUTE LIVER INJURY 81
CELLULE PROGENITRICI EPATICHE ESPRIMONO SERPINB3 IN UN MODELLO MURINO DI EPATITE FULMINANTE 80
EVALUATION OF THE ANALYTICAL SPECIFICITY OF SCCA-IGM ASSAY FOR MONITORING PATIENTS WITH CIRRHOSIS 80
The risk of overdiagnosis of antiphospholipid syndrome 77
MATRIX METALLOPROTEINASE 9 (MMP9)-IgM COMPLEX: AN EMERGING NOVEL BIOMARKER IN COLORECTAL CANCER 77
ESPRESSIONE DI TGF-b1 NELLA MALATTIA EPATICA EVOLUTIVA 77
SERPINB3 AND TGF-BETA IN CHRONIC LIVER DISEASE 77
SerpinB3 administration protects liver against ischemia-reperfusion injury 74
Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. 74
IMPROVED DETECTION OF HCC BY CO-DETERMINATION OF IgM ANTI-AFP ANTIBODIES AND AFP-IgM IMUNE COMPLEXES 74
SERPINB3 UP-REGULATION BY HYPOXIA IN HEPG2 CELLS : A HIF-2ALPHA AND REDOX SENSITIVE EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 71
Initiation of warfarin treatment in outpatients with nonrheumatic atrial fibrillation: a scheme for early prediction of maintenance dose 70
Totale 11.211
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.946
article - articoli 34.633
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 451
Totale 76.030
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021967 0 0 30 89 20 95 24 85 175 178 136 135
2021/20221.151 20 151 106 99 57 78 59 103 74 17 126 261
2022/20231.148 239 122 61 115 177 165 6 72 131 11 35 14
2023/2024563 22 98 64 36 44 79 38 27 12 17 58 68
2024/20252.717 18 257 115 107 285 77 139 191 217 113 480 718
2025/20262.679 471 873 1.335 0 0 0 0 0 0 0 0 0
Totale 12.470